Subgroups according to BASDAI/ASDAS category (baseline)

Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA - Tomas Milota, Jana Hurnakova, Karel Pavelka, Zlatuse

Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis, Health and Quality of Life Outcomes

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis

The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology

New evidence on the management of spondyloarthritis

Disease activity status at baseline stratified by BASDAI and ASDAS.

Change from baseline to week 12 in patient-reported outcomes by ASDAS

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central–eastern Europe

Disease Control Data, Ankylosing Spondylitis

Refining the Focus: A New Look at Spondylitis

A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis, Arthritis Research & Therapy

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5